Therapeutic potential of Yersinia anti-inflammatory components.
Microbial pathogens have developed various stratagems for modulating and/or circumventing the host's innate and adaptive immunity. Hence, certain virulence factors can be viewed as potential therapeutic agents for human immunopathological diseases. This is the case for virulence plasmid-encoded proteins from pathogenic Yersiniae that inhibit the host's inflammatory response by interfering with various cellular signaling pathways.
Foligné
Benoit
B
Inserm U801, Faculté de Médecine--Institut Pasteur de Lille, Université de Lille, France. benoit.foligne@ibl.fr
Dessein
Rodrigue
R
Marceau
Michaël
M
Poiret
Sabine
S
Dewulf
Joëlle
J
Pot
Bruno
B
Simonet
Michel
M
Daniel
Catherine
C
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D003092:Colitis / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy; D013294:Lactococcus lactis / Q000235:genetics / Q000276:immunology; D051379:Mice; D052899:Pore Forming Cytotoxic Proteins / Q000235:genetics / Q000276:immunology; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity; D037521:Virulence Factors / Q000627:therapeutic use*; D015007:Yersinia / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity
D000942:Antigens, Bacterial; C043908:LcrV protein, Yersinia; D052899:Pore Forming Cytotoxic Proteins; D037521:Virulence Factors; D014302:Trinitrobenzenesulfonic Acid